AHCO Stock Forecast: AdaptHealth Corp. Price Predictions for 2026-2027
The 7 Wall Street analysts covering AdaptHealth Corp. hold a median 12-month price target of $9 — +25.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 68 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores AdaptHealth Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (23): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
AHCO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AHCO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +25.0% from it.
Of the 20 most recent actions, 2 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Nov 2026 | Leerink Partners | Maintains | Outperform | $7.00 → $8.00 |
| 4 Nov 2026 | UBS | Maintains | Buy | $10 → $9.00 |
| 17 Sept 2026 | Baird | Maintains | Outperform | $10 → $9.00 |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | $15 → $8.00 |
| 6 Aug 2026 | UBS | Maintains | Buy | $14 → $10 |
| 5 Aug 2026 | Truist Securities | Maintains | Buy | $14 → $9.00 |
| 21 July 2026 | Jefferies | Upgrade | Buy | $11 → $13 |
| 6 July 2026 | Baird | Maintains | Outperform | $18 → $15 |
| 11 May 2026 | RBC Capital | Maintains | Outperform | — |
| 6 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 6 May 2026 | UBS | Maintains | Buy | — |
| 13 Apr 2026 | Truist Securities | Maintains | Buy | — |
| 26 Feb 2026 | Leerink Partners | Maintains | Outperform | — |
| 6 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 12 May 2025 | Truist Securities | Maintains | Buy | — |
| 8 May 2025 | RBC Capital | Maintains | Outperform | — |
| 27 Feb 2025 | Baird | Maintains | Outperform | — |
| 26 Feb 2025 | Canaccord Genuity | Maintains | Buy | — |
| 26 Feb 2025 | RBC Capital | Maintains | Outperform | — |
| 26 Feb 2025 | Truist Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AHCO.
This page is one stock. Monday covers all of them.
AHCO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
AHCO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, AdaptHealth Corp. returned −21.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
AHCO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.3×
- Price / book
- 0.8×
- EV / EBITDA
- 5.1×
Cheaper than 87% of US stocks
Cheaper than 78% of US stocks
Cheaper than 82% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- −12.1%
- Operating margin
- 3.8%
- Net margin
- −11.8%
Higher than 3% of US stocks
Higher than 50% of US stocks
Higher than 20% of US stocks
- Return on equity
- −28.4%
- Return on assets
- 1.9%
- Dividend yield
- —
Higher than 29% of US stocks
Higher than 57% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AdaptHealth Corp. has a market value of $983.0M and an enterprise value of $2.9B.
Revenue in the twelve months to 30 June 2026: $3.3B. The latest quarter shrank 4.1% year on year.
Net income over the same four quarters: −$223.4M, a −6.9% net margin.
Diluted earnings per share, trailing twelve months: −$1.71.
Free cash flow in the twelve months to 30 June 2026: $97.7M.
AdaptHealth Corp. employs 10,900 people — $299K of revenue per employee.
Data provided by Twelve Data
AHCO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at AHCO’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own AdaptHealth Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about AHCO
What is the AHCO stock price forecast for 2026-2027?
The 7 Wall Street analysts covering AdaptHealth Corp. have a median 12-month price target of $9, with estimates ranging from $8 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AHCO stock a buy right now?
Of the 7 analysts covering AdaptHealth Corp., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AdaptHealth Corp. 68 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AHCO?
As at 21 Nov 2026, AdaptHealth Corp. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).
Will AHCO stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts implies +25.0% from the last close, and Ticker Nerd's factor model ranks AdaptHealth Corp. 68 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AHCO stock forecast for 2030?
No analyst covering AdaptHealth Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AHCO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $10 over the next 12 months.
How has AHCO stock performed over the past year?
AdaptHealth Corp. returned -21.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does AdaptHealth Corp. do?
AdaptHealth Corp. is a healthcare services company that provides home medical equipment, medical supplies, and related patient support services across the United States. The company focuses on care delivered outside the hospital through offerings in sleep health, respiratory health, diabetes health, and wellness at home.
About AdaptHealth Corp.
AdaptHealth Corp. is a healthcare services company that provides home medical equipment, medical supplies, and related patient support services across the United States. The company focuses on care delivered outside the hospital through offerings in sleep health, respiratory health, diabetes health, and wellness at home. Its products and services include sleep therapy equipment, oxygen and ventilation systems, continuous glucose monitors, insulin pumps, and a broad range of durable medical equipment used in chronic and post-acute care. AdaptHealth works with Medicare, Medicaid, and commercial insurance patients, serving individuals who need recurring medical support in the home. The company plays an important role in the healthcare-at-home market by helping patients manage ongoing conditions with equipment, supplies, and service coordination tailored to home-based care.
CEO Ms. Suzanne M. Foster M.P.H. · 10,900 employees · United States · https://adapthealth.com